Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 11:15:2889-2900.
doi: 10.2147/COPD.S269637. eCollection 2020.

Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies

Thomas P Lodise  1 , Jingyi Li  2 , Hitesh N Gandhi  3 , Gerald O'Brien  3 , Sanjay Sethi  4
Affiliations

Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies

Thomas P Lodise et al. Int J Chron Obstruct Pulmon Dis. .

Abstract

Background: Inhaled corticosteroids (ICS) are widely used and recommended to treat chronic obstructive pulmonary disease (COPD). While generally considered safe, several studies demonstrated an increased risk of pneumonia with the use of ICS in COPD patients. Although all ICS indicated for COPD carry the class labeling warning of increased pneumonia risk, evidence suggests an intraclass difference in the risk of pneumonia between inhaled budesonide and fluticasone. To date, systematic reviews of direct-comparison studies have not been performed to assess if an intraclass difference exists.

Research question: This review investigated whether there is an intraclass difference in risk of pneumonia between inhaled fluticasone and budesonide, the 2 most commonly used ICS in COPD.

Study design and methods: A search of the medical literature was conducted in PubMed and Embase for the time period of 01/01/69-05/31/19. The search strategy combined terms that defined the patient/disease type, exposures, outcome, and the study/publication type. Descriptive and comparative statistics reported for fluticasone- and budesonide-containing products in each study, including data for pneumonia event subgroups, were extracted and reported by dose, seriousness, or practice setting. Controlled clinical trials and observational studies meeting the inclusion criteria were assessed for methodologic quality by using the appropriate tool from the list of study quality assessment tools developed by the National Institutes of Health.

Results: The summary relative risk (RR) ratio across 5 included studies (57,199 patients) was 1.13 (95% CI: 1.09-1.19), representing a 13.5% increased risk of pneumonia among fluticasone users compared to budesonide users. Similarly, summary RR ratio for serious pneumonia implied a 14.4% increased risk of serious pneumonia among fluticasone users compared to budesonide users (pooled RR: 1.14; 95% CI: 1.09-1.20).

Interpretation: There is likely a clinically important intraclass difference in the risk of pneumonia between fluticasone- and budesonide-containing inhaled medications in COPD.

Keywords: COPD; inhaled corticosteroids; pneumonia.

PubMed Disclaimer

Conflict of interest statement

Jingyi Li and Hitesh Gandhi are employees of AstraZeneca. Gerald O’Brien was an employee of AstraZeneca at the time of this study; he is now affiliated with Liquidia Technologies, Morrisville, NC. Thomas P Lodise is a consultant for AstraZeneca. Dr. Sethi has received research funding (to Jacobs School of Medicine, University at Buffalo, State University of New York) from Cipla, Sanofi, and GlaxoSmithKline; has been a consultant and/or participated in advisory boards for AstraZeneca, Boehringer Ingelheim, Circassia, Gilead, GlaxoSmithKline, Merck, Nabriva, Novavax, Paratek, Sunovion, and Theravance; has been a consultant for Aradigm and Pulmonx; and has been a speaker for AstraZeneca, Boehringer Ingelheim, and GlaxoSmithKline. He has received royalties from UpToDate and Taylor and Francis. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Study selection diagram.
Figure 2
Figure 2
Risk of pneumonia associated with fluticasone and budesonide in head-to-head studies.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68(11):1029–1036. doi:10.1136/thoraxjnl-2012-202872 - DOI - PMC - PubMed
    1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2020 report). 2020. - PubMed
    1. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789. doi:10.1056/NEJMoa063070 - DOI - PubMed
    1. Sharafkhaneh A, Southard JG, Goldman M, Uryniak T, Martin UJ. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir Med. 2012;106(2):257–268. doi:10.1016/j.rmed.2011.07.020 - DOI - PubMed
    1. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med. 2007;176(2):162–166. doi:10.1164/rccm.200611-1630OC - DOI - PubMed

Publication types

MeSH terms